A Functional Genomic Platform for Discovery of Novel Targeting Strategies in Acute Myeloid Leukemia
PRECISION MEDICINE SEMINAR SERIES
May 3, 2019 | 2:00 to 3:00 p.m. | 5-125 Moos Tower (TC); 302 Heller Hall (Duluth via ITV)
Jeffrey Tyner is an associate professor in the Department of Cell & Developmental Biology and co-director of the translational oncology program at the Knight Cancer Institute at Oregon Health & Science University (OHSU). He attended undergraduate school at Grinnell College in Grinnell, Iowa, and graduate school at Washington University in St. Louis. His graduate work, focusing on asthma and respiratory viral infections, was conducted under the mentorship of Dr. Michael Holtzman. For his post-doctoral fellowship, Jeff joined Dr. Brian Druker’s laboratory at OHSU where he studied molecular mechanisms of leukemogenesis.
Dr. Tyner’s research is focused towards: 1) identification of cancer-causing gene targets in cancer patients and 2) identification of patient-tailored, gene-targeted therapies. To accomplish these objectives, he has spent the past decade developing and implementing a functional screening approach whereby primary cells from hematologic malignancy patients can be tested ex vivo for sensitivity to a library of small-molecule inhibitors. This assay has now been cumulatively applied to over 2,000 patient specimens, and this large data set has been leveraged to inform findings that offer new diagnostic and therapeutic options.